HNWAG
ADIL

High Net Worth Advisory Group’s Adial Pharmaceuticals ADIL Stock Holding History

High Net Worth Advisory Group’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2
Closed -$2K – 668
2022
Q1 		$2K Hold
2
– – ﹤0.01% 626
2021
Q4 		$3K Buy
+2
New +$3.94K ﹤0.01% 625

Other funds holding ADIL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

High Net Worth Advisory Group's ADIL Position: Q2 2022 in Review

High Net Worth Advisory Group sold out of Adial Pharmaceuticals (ADIL) in Q2 2022, closing a stake of 2 shares — an estimated $2K sold.

High Net Worth Advisory Group first reported a position in ADIL in Q4 2021 and held it in 2 quarters. The position peaked at $3K in Q4 2021. 25 funds tracked by Wall St. Rank hold ADIL as of Q2 2022.

  • High Net Worth Advisory Group reported no remaining Adial Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 2 Adial Pharmaceuticals shares in Q2 2022, an estimated $2K.
  • High Net Worth Advisory Group first reported a position in Adial Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • High Net Worth Advisory Group's Adial Pharmaceuticals position peaked at $3K in Q4 2021.
  • 25 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2022.

Based on High Net Worth Advisory Group's 13F filing for Q2 2022, filed 10 Aug 2022.